Practical check-up guide
An EBV Test in a Guangzhou Package: Ask Which Assay Is Listed
By MyChinaCheckup coordination team · Published
Package lists and medical sources checked 13 October 2026.
“EBV test” is not a complete assay name. In the Guangzhou package pages checked on 13 October 2026, the wording ranges from generic EB病毒 to antibody panels with unnamed components and individually named antibody tests. A Shanghai comparison row explicitly names EBV DNA. Combining these under a single “EBV included” tick would lose information that the published lists actually provide.
The practical task is to preserve the test identity before comparing offers. This article does not interpret EBV results, recommend testing for healthy travellers or describe a package item as proof that cancer is present or absent.
Why the name needs more than EBV
CDC describes tests for antibodies to specific EBV-associated antigens and stresses that interpreting antibody results requires clinical information. Its laboratory page discusses particular antibody types; that does not mean every package using “EBV” includes those same tests. CDC laboratory testing for EBV.
NCI separately identifies antibodies and DNA markers in its description of EBV testing. For a catalogue comparison, the safe conclusion is limited: a row explicitly naming DNA should stay distinct from one naming antibodies, and a generic row should stay unspecified. The NCI page is a clinical cancer-information resource, not a recommendation to buy EBV testing during travel. NCI nasopharyngeal cancer information, diagnostic tests section.
The wording found in 33 package pages
The following groups contain 32 Guangzhou pages with an explicit EBV-related row and one Shanghai reference. They were located within the 78-package corpus, then checked against complete current HTML tables and linked PDFs where provided. Grouping saves repetition; each package remains individually linked. These are catalogue names, not independently verified laboratory specifications.
Scroll horizontally to see all columns.
| Package pages | Published wording | What the wording establishes |
|---|---|---|
| Sun Yat-sen Memorial Men’s check-up 01, Men’s check-up 02, Men’s check-up 03, Women’s check-up 01, Women’s check-up 03 | Epstein–Barr virus tests | Assay unspecified; repeated wording in men-3 does not identify two assays |
| Zhujiang Men’s check-up 01, Men’s check-up 02, Women’s check-up 01, Women’s check-up 03 | Epstein–Barr virus tests | Assay unspecified |
| Guangzhou First People’s Men’s check-up 02, Men’s check-up 03, Women’s check-up 02, Women’s check-up 03 | Epstein–Barr virus tests | Assay unspecified |
| Nanfang Men’s check-up 01, Men’s check-up 02, Women’s check-up 01, Women’s check-up 02, Women’s check-up 03 | Epstein–Barr virus tests (capsid antigen IgA) | Preserve capsid antigen IgA wording; do not relabel it IgG, IgM or DNA |
| Guangzhou Medical University First Affiliated Men’s Select 03, Women’s Select 03 | EB病毒抗体两项检测(NA-IgA、VCA-IgA) | Two names supplied: NA-IgA and VCA-IgA; retain the source spelling |
| Clifford Men’s Basic 01, Women’s Basic 01 | EB病毒抗体 | Antibodies named; subtype unspecified |
| Clifford Men’s Advanced 02, Men’s Select 03, Women’s Advanced 02, Women’s Select 03 | EB病毒抗体测定 plus EB病毒Rta-IgG测定 | One generic antibody row and a separate Rta-IgG row; the generic row remains unspecified |
| Guangdong Second Provincial, Pazhou Men’s Basic 01, Women’s Basic 01 | EB病毒 | Generic EBV test; specific assay requires confirmation |
| Guangdong Second Provincial, Pazhou Men’s Advanced 02, Men’s Selected 03 | EB病毒抗体二项 | Two antibody items, but the components are unnamed |
| Guangdong Second Provincial, Pazhou Women’s Advanced 02, Women’s Selected 03 | EB病毒抗体 | Antibodies named; specific antibody assay unresolved |
| Renji East, Shanghai Men’s check-up 03 | Epstein–Barr virus DNA / DNA-EB病毒 | DNA explicitly named; specimen, platform and reporting method not established by this row |
Four places where a comparison can go wrong
A generic entry gets silently upgraded
Pazhou Basic 01 says EB病毒, with the English catalogue explicitly asking for assay confirmation. It should not become “EBV DNA included” in a spreadsheet or booking summary. The Renji East row provides a useful contrast because DNA is actually printed there. A shared virus name does not supply the missing test specification.
Two unnamed items get assigned familiar names
Pazhou men’s Advanced 02 and Selected 03 name a two-item antibody panel but do not list its components. GMU Select 03 does list NA-IgA and VCA-IgA. Copying those names across providers would turn one provider’s explicit wording into an unsupported claim about another. The two-item count is not enough.
A heading becomes a diagnostic promise
Clifford Basic 01 has a summary heading using 鼻咽癌筛查, while its detailed row says EB病毒抗体. The heading does not identify an antibody subtype. Keep the detailed laboratory wording and ask for the missing specification rather than converting the heading into “complete cancer screening.” NCI’s description of diagnosis involves clinical assessment and other examinations, including tissue examination; this catalogue audit supplies none of those findings. NCI nasopharyngeal cancer information.
Repetition gets counted as a second known assay
Sun Yat-sen Memorial men’s 03 repeats the same generic EBV wording in the reviewed table. That is a source-layout observation. Without distinct assay names, it cannot justify reporting two identified EBV tests. Similarly, Clifford’s Rta-IgG row is separately named, but it does not resolve the subtype of the neighbouring generic antibody measurement.
Keep the abbreviation exactly as supplied
For Nanfang, retain the source’s capsid antigen IgA wording. For GMU, retain NA-IgA and VCA-IgA; do not silently expand or “correct” NA to another abbreviation. For Clifford, retain Rta-IgG. These labels are sufficient to expose differences between lists without adding unsupported claims about clinical performance, cancer detection or equivalent methods.
The CDC explainer is useful background for why an antigen and antibody class matter. It should not be used to substitute its IgG or IgM discussion for the catalogue’s IgA wording, or to interpret a local assay that has not been specified. CDC laboratory testing for EBV.
A focused question list for the package owner
Ask for the full assay name in Chinese and English, rather than “Is EBV included?” Then record:
- Whether the named item is a DNA test, an antibody test, or still unspecified.
- For antibodies, each antigen/target and antibody class stated by the laboratory.
- For a panel, every component rather than only the item count.
- The specimen and reporting format the provider actually supplies.
- Whether method details are available if your reviewing clinician needs them.
- Who will explain the result and whether that review is included in the written plan.
Leave unanswered fields marked “awaiting confirmation.” Do not resolve them by borrowing a different package’s wording, a search-result description or a general medical article. You do not need to attach identity documents or a full medical history to ask what a published item name means.
Scope and limits
The linked PDFs are MyChinaCheckup-branded catalogue documents, not hospital-issued specifications or independent hospital confirmation.
The table reports only pages with an explicit matching row. A page omitted here is not a confirmed exclusion, and the audit is not a comprehensive hospital laboratory directory. It makes no claim about current assay availability, laboratory platform, suitability, accuracy, turnaround or cancer-detection performance. For the broader distinction between a commercial list and a clinical screening decision, use the cancer-screening discussion guide.
Continue planning
Use the Guangzhou check-up planning page for the city and booking context, and the package-comparison guide for the complete written proposal. A directory row is a reference for asking precise questions; it does not confirm an appointment, a current quotation or personal medical suitability.